| 1 |
31444987 | Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study. | 2020 Feb |
1 |
| 2 |
27424313 | Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. | 2016 Oct 15 |
1 |
| 3 |
26031507 | The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia. | 2015 Oct |
2 |
| 4 |
23563040 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. | 2013 |
1 |
| 5 |
23144467 | Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. | 2012 Dec |
1 |
| 6 |
21675801 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. | 2011 Aug 1 |
1 |
| 7 |
21942979 | Fenofibrate: a review of its use in dyslipidaemia. | 2011 Oct 1 |
1 |
| 8 |
24331137 | Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. | 2011 Oct-Dec |
1 |
| 9 |
19396049 | Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes. | 2009 May |
3 |
| 10 |
19555253 | Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. | 2009 Aug |
1 |
| 11 |
17209672 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. | 2007 |
1 |
| 12 |
17522372 | Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. | 2007 Spring |
2 |
| 13 |
18650989 | Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. | 2007 Summer |
3 |
| 14 |
16875159 | [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia]. | 2006 May |
1 |
| 15 |
15877299 | The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. | 2005 May |
2 |
| 16 |
15920062 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. | 2005 Jun |
1 |
| 17 |
16123850 | The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. | 2005 Jun |
1 |
| 18 |
14764586 | Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. | 2004 Apr 16 |
2 |
| 19 |
15136070 | Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. | 2004 Jun |
1 |
| 20 |
11942772 | Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. | 2002 Mar-Apr |
1 |
| 21 |
12017210 | The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. | 2002 |
1 |
| 22 |
12666442 | [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia]. | 2002 Dec |
1 |
| 23 |
11770837 | Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. | 2001 Dec |
1 |
| 24 |
10216095 | Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. | 1999 May 1 |
4 |
| 25 |
10353071 | Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. | 1999 Apr |
1 |
| 26 |
10460070 | Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. | 1999 Aug |
3 |
| 27 |
9655393 | Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. | 1998 Jun 25 |
1 |
| 28 |
8843189 | Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. | 1996 Oct |
1 |
| 29 |
8847874 | Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. | 1996 Apr |
1 |
| 30 |
7857385 | Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. | 1994 Oct |
1 |
| 31 |
8117177 | Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. | 1994 Feb 28 |
2 |
| 32 |
8236126 | Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. | 1993 Aug 2 |
2 |
| 33 |
2731478 | [Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?]. | 1989 Jun 16 |
2 |